Caladrius Q2 net loss $6.6M; merger with Cend on track for Q3 2022 forming Lisata Therapeutics

LISATA THERAPEUTICS, INC.

2022-Q2 EPS reported -$0.18

Net loss $6.6M vs $5.7M YoY; cash $73M after $10M Cend investment.
Merger with Cend expected to close Q3 2022, pending stockholder approval; new ticker LSTA.
HONEDRA pre-consultation with PMDA; XOWNA FREEDOM trial enrollment suspended, interim analysis in Q3.
CLBS201 DKD trial fully enrolled (6 patients), top-line data expected Q1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.